UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000060788 |
|---|---|
| Receipt number | R000069484 |
| Scientific Title | Prognostic Significance of Postoperative and Post-Adjuvant Circulating Tumor DNA in Resected Colon Cancer: A Systematic Review and Meta-Analysis |
| Date of disclosure of the study information | 2026/03/01 |
| Last modified on | 2026/03/01 13:50:09 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Prognostic Significance of Postoperative and Post-Adjuvant Circulating Tumor DNA in Resected Colon Cancer: A Systematic Review and Meta-Analysis
Acronym
Prognostic Significance of Postoperative and Post-Adjuvant Circulating Tumor DNA in Resected Colon Cancer: A Systematic Review and Meta-Analysis
Scientific Title
Prognostic Significance of Postoperative and Post-Adjuvant Circulating Tumor DNA in Resected Colon Cancer: A Systematic Review and Meta-Analysis
Scientific Title:Acronym
Prognostic Significance of Postoperative and Post-Adjuvant Circulating Tumor DNA in Resected Colon Cancer: A Systematic Review and Meta-Analysis
Region
| Japan | Asia(except Japan) | North America |
| South America | Australia | Europe |
| Africa |
Condition
Condition
Colon Cancer
Classification by specialty
| Gastroenterology | Gastrointestinal surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
Prognostic Accuracy of ctDNA in the Postoperative and Post-Adjuvant Chemotherapy Settings of Colon Cancer
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Prognostic Accuracy
Key secondary outcomes
Base
Study type
Others,meta-analysis etc
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
The eligibility criteria were defined as follows. Studies were included if they met all of the following conditions: (1) patients with colon cancer who underwent curative-intent surgery; (2) postoperative ctDNA testing performed using plasma samples only; and (3) an observational (prospective or retrospective cohort) or randomized controlled trial design.
Key exclusion criteria
Studies were excluded if: (1) they reported updated results from previously published cohorts without providing independent data; (2) outcome data were not extractable or were insufficient to estimate effect sizes; or (3) the primary focus was cost-effectiveness analysis rather than prognostic outcomes.
Target sample size
1000
Research contact person
Name of lead principal investigator
| 1st name | En |
| Middle name | |
| Last name | Wang |
Organization
Asakayama General Hospital
Division name
Department of Surgery
Zip code
590-0018
Address
3-3-16 Imaikecho, Sakai-ku, Sakai City, Osaka
TEL
81-72-229-4882
wangen.cn@gmail.com
Public contact
Name of contact person
| 1st name | En |
| Middle name | |
| Last name | Wang |
Organization
Asakayama General Hospital
Division name
Department of Surgery
Zip code
590-0018
Address
3-3-16 Imaikecho, Sakai-ku, Sakai City, Osaka
TEL
81-72-229-4882
Homepage URL
wangen.cn@gmail.com
Sponsor or person
Institute
Asakayama General Hospital
Institute
Department
Personal name
Funding Source
Organization
Sef funding
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Asakayama General Hospital IRB
Address
3-3-16 Imaikecho, Sakai-ku, Sakai City, Osaka 590-0018, Japan
Tel
+81-72-229-4882
wangen.cn@gmail.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2026 | Year | 03 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Suspended
Date of protocol fixation
| 2026 | Year | 01 | Month | 01 | Day |
Date of IRB
| 2026 | Year | 03 | Month | 01 | Day |
Anticipated trial start date
| 2026 | Year | 03 | Month | 01 | Day |
Last follow-up date
| 2027 | Year | 03 | Month | 01 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
None
Management information
Registered date
| 2026 | Year | 03 | Month | 01 | Day |
Last modified on
| 2026 | Year | 03 | Month | 01 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069484
